Regadenoson is a pharmacologic cardiac stress test agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. It is available as injection for intravenous use. MedsAcross supplies Regadenoson for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LEXISCAN ® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. LEXISCAN ® is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.
Source: US FDA prescribing information
Regadenoson is a low affinity agonist (K i ≈ 1.3 µM) for the A 2A adenosine receptor, with at least 10-fold lower affinity for the A 1 adenosine receptor (K i > 16.5 µM), and weak, if any, affinity for the A 2B and A 3 adenosine receptors. Activation of the A 2A adenosine receptor by regadenoson produces coronary vasodilation and increases coronary blood flow (CBF).
Source: US FDA prescribing information
The recommended dose of LEXISCAN is 5 mL (0.4 mg regadenoson) administered as an intravenous injection within 10 seconds. • Patients should be instructed to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, aminophylline and theophylline for at least 12 hours before a scheduled radionuclide MPI. • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer LEXISCAN if it contains particulate matter or is discolored. • Administer LEXISCAN as an intravenous injection within 10 seconds into a peripheral vein using a 22 gauge or larger catheter or needle. • Administer a 5 mL saline flush immediately after the injection of LEXISCAN.
Source: US FDA prescribing information
Do not administer LEXISCAN to patients with: • Second- or third-degree AV block, or • sinus node dysfunction unless these patients have a functioning artificial pacemaker. Do not administer LEXISCAN to patients with: • Second- or third-degree AV block, or • sinus node dysfunction unless the patients have a functioning artificial pacemaker.
Source: US FDA prescribing information
• Myocardial Ischemia. Fatal cardiac events have occurred. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability, who may be at greater risk. Cardiac resuscitation equipment and trained staff should be available before administration. • Sinoatrial (SA) and Atrioventricular (AV) Nodal Block. Adenosine receptor agonists, including LEXISCAN, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia. • Atrial Fibrillation/Atrial Flutter. New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported. • Hypersensitivity, including anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, and rashes have occurred.
Source: US FDA prescribing information
The following adverse reactions are discussed in more detail in other sections of the labeling. • Myocardial Ischemia • Sinoatrial and Atrioventricular Nodal Block • Atrial Fibrillation/Atrial Flutter • Hypersensitivity, Including Anaphylaxis • Hypotension • Hypertension • Bronchoconstriction • Seizure • Cerebrovascular Accident (Stroke) The most common (incidence ≥ 5%) adverse reactions to LEXISCAN are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea.
Source: US FDA prescribing information
No formal pharmacokinetic drug interaction studies have been conducted with LEXISCAN. • Methylxanthines, e.g., caffeine, aminophylline and theophylline, interfere with the activity of LEXISCAN. • Aminophylline may be used to attenuate severe and/or persistent adverse reactions to LEXISCAN. • Dipyridamole may increase the activity of LEXISCAN. When possible, withhold dipyridamole for at least two days prior to LEXISCAN administration.
Source: US FDA prescribing information
Store at controlled room temperature, 25°C (77°F), excursions permitted to 15° to 30°C (59°– 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Regadenoson, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Regadenoson 0.4 mg/5 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Lexiscan 0.4 mg/5 mL injectionIntravenous | Astellas Pharma | US FDA | Available on request |
| Regadenoson 0.08 mg/mL injectionIntravenousGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 3 presentations of Regadenoson and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Regadenoson, including Lexiscan.
Yes. The US FDA first approved Regadenoson on 10 April 2008, according to Drugs@FDA.
Yes. Regadenoson has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Regadenoson is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Regadenoson is classified under ATC code C01EB21 (Regadenoson).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.